Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Colorectal Neoplasms 5Pancreatic Neoplasms 4Breast Neoplasms 4Recurrence 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia 2Esophageal Neoplasms 2Burkitt Lymphoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

anlotinib 1Radiotherapy 1Immunotherapy 1Drug Therapy 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Locally Advanced Non-small Cell Lung Cancer × Drug Therapy × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡